{"product_id":"bioventus-pestle-analysis","title":"Bioventus PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE analysis pinpoints the political, economic, social, technological, legal and environmental forces reshaping Bioventus’s growth trajectory. It reveals regulatory risks, reimbursement dynamics, innovation drivers and sustainability pressures investors must monitor. Ideal for strategy, due diligence, or competitive benchmarking, it translates trends into actionable insight. Purchase the full PESTLE for the complete, ready-to-use breakdown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment funding priorities and reimbursement frameworks, including NIH's roughly $49.6 billion FY2024 budget and the ~64 million US Medicare beneficiaries in 2024, directly shape demand for orthobiologics and OA therapies. Policy shifts toward value-based care favor cost-effective, minimally invasive options and can boost uptake if tied to outcomes-based reimbursement. Changes in Medicare\/Medicaid coverage or national health service HTA decisions can accelerate or constrain adoption, so continuous engagement with policymakers and HTA bodies is critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational regulators set evidence thresholds and review timelines—FDA targets 90 days for 510(k) decisions and 180 days for PMA cycles, while the EU MDR came into full effect on May 26, 2021, tightening pre- and post-market requirements. Streamlined pathways like de novo can accelerate entry, whereas heightened scrutiny and political pressure after safety events often lead to added post-market obligations and reporting. Harmonization efforts via IMDRF, established in 2011, aim to align labeling and surveillance but progress is uneven across jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade and tariff exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTariffs on biomaterials, components and finished devices—average applied tariffs for medical devices in major markets around 2–4% per WTO—compress Bioventus margins on low-margin products. Export controls and customs delays (often adding 1–3 weeks) disrupt cross-border supply chains. Favorable trade pacts like USMCA or EU agreements can improve pricing competitiveness, while geopolitical tensions drive dual sourcing strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic procurement dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTenders and group purchasing in public systems set access and price benchmarks; OECD estimates public procurement at about 12% of GDP, and US GPOs oversee roughly $200 billion in healthcare contracts annually, shaping hospital purchasing. Political mandates for local sourcing, such as Buy American-style rules, influence manufacturing footprints and supplier selection. Transparency and anti-corruption standards (OECD and national rules) tightly govern bidding behavior, while multi-year framework agreements (commonly 3–5 years) provide volume visibility for capacity planning.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTenders\/GPOs: set price benchmarks; ~$200bn US healthcare contracts\u003c\/li\u003e\n\u003cli\u003ePublic procurement: ~12% of GDP (OECD)\u003c\/li\u003e\n\u003cli\u003eLocal sourcing mandates: affect manufacturing siting\u003c\/li\u003e\n\u003cli\u003eTransparency rules: govern bidding and compliance\u003c\/li\u003e\n\u003cli\u003eFrameworks: 3–5 year deals give volume visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability and supply chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConflicts, sanctions, and policy volatility threaten Bioventus supply of key polymers and surgical disposables by disrupting trade lanes and supplier contracts, increasing procurement risk and cost pressure.\u003c\/p\u003e\n\u003cp\u003ePolitical risks at sterilization and logistics hubs can create sterilization backlogs and transport bottlenecks, delaying product release and revenue recognition.\u003c\/p\u003e\n\u003cp\u003eIn crises governments often prioritize essential medtech allocations, shifting distribution and reimbursement dynamics; scenario planning and supplier diversification reduce disruption impact.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupply vulnerability: trade and sanctions risk\u003c\/li\u003e\n\u003cli\u003eSterilization\/logistics: concentration creates bottlenecks\u003c\/li\u003e\n\u003cli\u003ePolicy shifts: government prioritization alters allocations\u003c\/li\u003e\n\u003cli\u003eMitigation: scenario planning and supplier diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNIH \u003cstrong\u003e$49.6B\u003c\/strong\u003e, Medicare \u003cstrong\u003e~64M\u003c\/strong\u003e and FDA timelines shape market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment funding and reimbursement (NIH $49.6B FY2024; ~64M Medicare beneficiaries 2024) drive orthobiologics demand and favor value-based, cost-effective therapies. Regulatory timelines (FDA 90d 510(k)\/180d PMA; EU MDR effective 26‑May‑2021) and tariffs (~2–4% on devices) affect market access and margins. Public procurement\/GPOs (~12% GDP; US GPOs ~$200B) determine pricing and volume via 3–5 year frameworks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH budget\u003c\/td\u003e\n\u003ctd\u003e$49.6B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\u003c\/td\u003e\n\u003ctd\u003e~64M beneficiaries (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA timelines\u003c\/td\u003e\n\u003ctd\u003e90d 510(k)\/180d PMA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariffs\u003c\/td\u003e\n\u003ctd\u003e~2–4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\/procurement\u003c\/td\u003e\n\u003ctd\u003e~$200B \/ ~12% GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Bioventus across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—using current market and regulatory dynamics relevant to its orthobiologics and medtech operations. Designed for executives and investors, each section is data-backed, forward-looking, and formatted for direct use in strategy, funding pitches, or scenario planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBioventus PESTLE Analysis distills regulatory, market and technological risks into a clean, visually segmented summary for quick interpretation and team alignment. Its concise, shareable format makes it easy to drop into presentations or strategy sessions to relieve planning and risk-assessment bottlenecks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcedure volume sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElective and semi‑elective orthopedics fell up to 50% in early 2020, with procedures (hip\/knee ~1.2M annually pre‑pandemic in the US) rebounding to near pre‑pandemic levels by 2023; backlogs have triggered 20–40% short‑term surges post‑disruption. Hospital budget constraints frequently defer capital and premium purchases, so predictive demand planning helps align Bioventus inventory to these swings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and payer pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers increasingly demand lower prices and outcomes guarantees for OA and fracture solutions, pressuring manufacturers like Bioventus (2024 revenue ~USD 600M). Robust cost-effectiveness evidence supports formulary inclusion and helps stabilize average selling prices. Expansion of bundled payments shifts financial risk to providers and vendors, while value-based contracts can preserve market share but cap upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and input costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising inflation (US CPI 2024 +3.4%) and higher energy costs have pushed biomaterials, packaging and sterilization expenses up materially, squeezing margins. Wage inflation (average hourly earnings ~+4.1% in 2024) increases manufacturing and field support costs while contract terms mean price pass-throughs often lag by quarters. Bioventus targets productivity gains and product redesigns to offset COGS pressure, aiming for mid-single-digit cost improvements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobal sales expose Bioventus earnings to foreign exchange volatility, which can materially affect reported USD revenues and margins.\u003c\/p\u003e\n\u003cp\u003eA stronger US dollar tends to compress reported international revenues and margin percentages when translated to USD.\u003c\/p\u003e\n\u003cp\u003eBioventus uses natural hedges through local cost bases and selective financial hedging, and must set market prices reflecting each market’s FX pass-through ability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX exposure: impacts reported revenue and margins\u003c\/li\u003e\n\u003cli\u003eMitigants: local costs + financial hedging\u003c\/li\u003e\n\u003cli\u003ePricing: must reflect market-specific FX pass-through\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital access and interest rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigher interest rates raise Bioventus’s borrowing costs and elevate R\u0026amp;D and M\u0026amp;A hurdle rates; US federal funds were about 5.25–5.50% in mid‑2025, tightening capital availability and increasing discount rates used in valuations. Tighter provider financing constrains purchase of higher‑end solutions, while lower investor risk appetite compresses multiples, making disciplined capital allocation a key competitive advantage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher rates: federal funds ~5.25–5.50% (mid‑2025)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D\/M\u0026amp;A: higher hurdle rates, pricier debt\u003c\/li\u003e\n\u003cli\u003eProvider financing: reduced uptake of premium devices\u003c\/li\u003e\n\u003cli\u003eInvestor risk appetite: lower valuations, less strategic flexibility\u003c\/li\u003e\n\u003cli\u003eCapital allocation: decisive competitive edge\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNIH \u003cstrong\u003e$49.6B\u003c\/strong\u003e, Medicare \u003cstrong\u003e~64M\u003c\/strong\u003e and FDA timelines shape market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElective ortho rebounded to near pre‑pandemic volumes by 2023, creating 20–40% short‑term surges that challenge inventory and hospital budgets. Payers press for lower prices, outcomes guarantees and bundled payments, pressuring ASPs despite Bioventus’s ~USD 600M 2024 revenue. Inflation (CPI 2024 +3.4%), wage inflation (+4.1%) and higher input costs squeeze margins; fed funds ~5.25–5.50% (mid‑2025) raise financing costs. FX volatility and a stronger USD compress reported international revenue; local cost bases and hedging partially mitigate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioventus revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~USD 600M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hip\/knee procedures (pre‑pandemic)\u003c\/td\u003e\n\u003ctd\u003e~1.2M annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI (2024)\u003c\/td\u003e\n\u003ctd\u003e+3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWage inflation (2024)\u003c\/td\u003e\n\u003ctd\u003e+4.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (mid‑2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact\u003c\/td\u003e\n\u003ctd\u003eStronger USD compresses reported revenues\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eBioventus PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThis Bioventus PESTLE Analysis delivers a concise evaluation of the political, economic, social, technological, legal, and environmental factors shaping the company and its market position. It highlights key risks, regulatory impacts, and strategic opportunities for investors and business leaders. The preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162789556601,"sku":"bioventus-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/bioventus-pestle-analysis.png?v=1762708719","url":"https:\/\/portersfiveforce.com\/products\/bioventus-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}